Novartis Signs an Agreement with NHS to Commercialize Leqvio (inclisiran) for the Treatment of Cardiovascular Disease
Novartis Entered into a Collaboration and License Agreement with Dunad to Develop Oral Targeted Protein Degrader Therapies
Shots:
- The agreement follows the NICE recommendation to deliver Leqvio via a population health management approach for high-risk cardiovascular patients across England
- The NICE recommendation was based on Novartis’s ORION clinical research program including P- III trials ORION-9/10/11 evaluating the safety, efficacy, and tolerability of inclisiran in 3,600 patients with CVD which showed that the therapy-maintained LDL-C reduction through 6mos. dosing interval
- Inclisiran is the 1st siRNA therapy for the reduction of LDL-C levels via RNAi & is licensed in the EU for the treatment of adults with primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet
Click here to read full press release/ article | Ref: Novartis | Image: BioProcess International